

## THE MTA STAR LISTING PROCESS: AMENDMENT TO THE EXISTING SHAREHOLDERS' AGREEMENT AND COMMITMENT TO THE 36 MONTHS LOCK UP BY SHAREHOLDERS OF REFERENCE

Pisa, 27<sup>th</sup> October 2020 - [PharmaNutra S.p.A.](#) (the "Company"), notifies that today - as part of the MTA market listing process and in order to consent to compliance with the free float requirements set by the STAR segment - the **shareholders' agreement in force** (signed on 12<sup>th</sup> July 2017 during admission to AIM Italia) has been amended foreseeing: (i) termination of agreement effects for parties other than the shareholders of reference and chief executive officers of the company (jointly, the "Shareholders of Reference") Andrea Lacorte, Roberto Lacorte and Carlo Volpi (through Beda S.r.l.); and (ii) the amendments to the agreement which will be effective amongst Shareholders of Reference as of the date Company shares start trading on the MTA.

The agreement between the Shareholders of Reference thus amended, regarding shares representing a total of 64.99% of the Company's share capital, will last for 36 months from the date Company shares start trading on the MTA. It establishes governance provisions of the Issuer itself, especially referred to how the Board of Directors and Board of Statutory Auditors are appointed; and a lock up commitment, taken by the Shareholders of Reference with the Company for the 36 months following the date trading on the MTA starts, except for some exceptions specifically established therein.

After Company shares have started trading on the MTA, the agreement will comply with publicity obligations pursuant to regulations applicable.

**PharmaNutra S.p.A.**

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b  
56122 Pisa  
Tel. +39 050 7846500  
[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)  
Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

**Nomad  
CFO SIM S.p.A.**

Via dell'Annunciata, 23/4  
20121 Milan  
Tel. +39 02 303431  
[ecm@cfsim.com](mailto:ecm@cfsim.com)

**Press Office  
Spriano Communication & Partners**

Via Santa Radegonda, 16  
20121 Milan  
Tel. +39 02 83635708  
  
Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)